Could ketamine speed up depression relief in hospitalized patients?
NCT ID NCT06508710
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests whether adding intravenous ketamine to the antidepressant venlafaxine can relieve severe depression faster than venlafaxine alone. Sixty hospitalized adults with major depression will receive either ketamine or placebo infusions over one week. The goal is to see if ketamine can improve symptoms within days, potentially shortening hospital stays and reducing suffering.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ketamine
What this could lead to
If it works, this could provide a faster way to relieve severe depression in hospitalized patients, potentially reducing suffering and hospital stays.
What could go wrong
This is a small, early-phase trial with only 60 participants. Ketamine may not work better than placebo, and side effects like dissociation or blood pressure changes are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE EPISODE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bicetre Hospital - CRC
NOT_YET_RECRUITINGLe Kremlin-Bicêtre, 94250, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CEA/SHFJ
ACTIVE_NOT_RECRUITINGOrsay, 94401, France
-
EPS Barthélémy Durand
NOT_YET_RECRUITINGÉtampes, 91152, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Psychiatry unit
RECRUITINGLe Kremlin-Bicêtre, France, 94270, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact